Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA4 | P22748 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL4961752 | 0.94 | CA12 (0.33) | CA12CA1CA2CA4CA9 | |
| SCHEMBL2480926 | 0.94 | CA12 (0.39) | CA12CA1CA2CA4CA9 | |
| SCHEMBL221310 | 0.88 | — | — | |
| Nitric Acid SCHEMBL219749 | 0.86 | MEN1 (0.36) | MEN1CYP2C9ALOX15CYP2C19KMT2A | |
| Nitric Acid SCHEMBL4691871 | 0.79 | MEN1 (0.33) | MEN1CYP2C9ALOX15CYP2C19KMT2A | |
| SCHEMBL3863882 | 0.79 | — | — | |
| Nitric Acid SCHEMBL27870521 | 0.76 | ALDH1A1 (0.45) | CA12CA1CA2CA4CA9 | |
| Nitric Acid SCHEMBL15056866 | 0.76 | ALDH1A1 (0.45) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1220763 | 0.76 | CA12 (0.48) | CA12CA1CA2CA4CA9 | |
| Nitric Acid SCHEMBL3326614 | 0.75 | CA12 (0.40) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729115-B2 | Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases | CARDIOLYNX AG (CH) | 2014-05-20 | — | — | US | disclosed |
| US-20130041001-A1 | VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | CARDIOLYNX AG (CH) | 2013-02-14 | — | — | US | disclosed |
| EP-2377855-B1 | A valsartanamide dinitrate derivative for the treatment of vascular and metabolic diseases | CARDIOLYNX AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011131613-A1 | VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | CARDIOLYNX AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| EP-2377855-A1 | A valsartanamide dinitrate derivative for the treatment of vascular and metabolic diseases | Cardiolynx AG (CH) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041001-A1 | VALSARTAN DERIVATIVES CARRYING NITROGEN OXIDE DONORS FOR THE TREATMENT OF VASCULAR AND METABOLIC DISEASES | GLS, REN, NAT1 | CA12 2042/4885CA1 2009/4885CA2 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.